1-6 of 6
Gregory M. Cote
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors

Gregory M. Cote, Bose S. Kochupurakkal, Khanh Do, Andrea Bullock, Michael L. Cheng, Alona Muzikansky, Daniel E. McLoughlin, James M. Cleary, Xin Gao, Aparna Parikh, Jong Chul Park, Colin D. Weekes, Oladapo Yeku, Lee Zou, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2024)
https://doi.org/10.1158/1078-0432.CCR-24-1867
Published: 25 October 2024
View article titled, A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors
Open the PDF for A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma

Gregory M. Cote, Candace L. Haddox, Edwin Choy, Priscilla A. Merriam, Emanuele Mazzola, Vinayak Venkataraman, Thierry Alcindor, Andrew J. Wagner, George D. Demetri, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (13): 2702–2708.
https://doi.org/10.1158/1078-0432.CCR-24-1037
Published: 01 July 2024
View article titled, Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma
Open the PDF for Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Candace L. Haddox, Michael J. Nathenson, Emanuele Mazzola, Jia-Ren Lin, Joanna Baginska, Allison Nau, Jason L. Weirather, Edwin Choy, Adrian Marino-Enriquez, Jeffrey A. Morgan, Gregory M. Cote, Priscilla Merriam, Andrew J. Wagner, Peter K. Sorger, Sandro Santagata, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1281–1292.
https://doi.org/10.1158/1078-0432.CCR-23-2250
Published: 01 April 2024
View article titled, Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
Open the PDF for Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates in another window
Includes: Supplementary data
Journal Articles

Abstract A019: Phase 1, first-in-human, dose-expansion study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients with sarcoma

Andrew J. Wagner, Gregory M. Cote, Donald Richards, Nicholas J. Vogelzang, William J. Edenfield, Mitchell E. Gross, Lynn Mar, Gil D. Fine, Edward Dow, John A. Charlson
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): A019.
https://doi.org/10.1158/1557-3265.SARCOMAS22-A019
Published: 15 September 2022
View article titled, Abstract A019: Phase 1, first-in-human, dose-expansion study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients with sarcoma
Journal Articles

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

William D. Tap, Arun S. Singh, Stephen Patrick Anthony, Mike Sterba, Chao Zhang, John H. Healey, Bartosz Chmielowski, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Zev A. Wainberg, Igor Puzanov, Gregory M. Cote, Andrew J. Wagner, Fadi Braiteh, Eric Sherman, Henry H. Hsu, Charles Peterfy, Heather L. Gelhorn, Xin Ye, Paul Severson, Brian L. West, Paul S. Lin, Sandra Tong-Starksen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 298–307.
https://doi.org/10.1158/1078-0432.CCR-21-2007
Published: 15 January 2022
View article titled, Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
Open the PDF for Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT in another window
Includes: Supplementary data
Journal Articles

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Ingo K. Mellinghoff, Marta Penas-Prado, Katherine B. Peters, Howard A. Burris, III, Elizabeth A. Maher, Filip Janku, Gregory M. Cote, Macarena I. de la Fuente, Jennifer L. Clarke, Benjamin M. Ellingson, Saewon Chun, Robert J. Young, Hua Liu, Sung Choe, Min Lu, Kha Le, Islam Hassan, Lori Steelman, Shuchi S. Pandya, Timothy F. Cloughesy, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4491–4499.
https://doi.org/10.1158/1078-0432.CCR-21-0611
Published: 15 August 2021
View article titled, Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Open the PDF for Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial in another window
Includes: Supplementary data